T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective

Chronic lymphocytic leukemia: an historical perspective.

See the related ASH 50th Anniversary Review articles under the ACUTE AND CHRONIC LEUKEMIAS section of the publication ASH 50th Anniversary Reviews: A Salute to the American Society of Hematology. Despite the major advances that have been made on the molecular pathogenesis, diagnosis and treatment of chronic lymphocytic leukemia (CLL) it is remarkable how much of the current approach to manageme...

The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.

Chronic lymphocytic leukemia is marked by profound defects in T-cell function. Programmed death-1 is a receptor involved in tumor-mediated immunosuppression through binding of the PD-L1 ligand. Multiparametric flow cytometry and immunohistochemistry were used to study PD-1/PD-L1 expression. Functional assays were used to determine the involvement of the PD-1/PD-L1 axis in T-cell responses. PD-1...

CD4+ T Cells are Exhausted and Show Functional Defects in Chronic Lymphocytic Leukemia

Background: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. This health problem is caused due to the accumulation of mature B-lymphocytes in the peripheral blood and bone marrow. In the course of cancer, CD4+ T cells become “exhausted” and characterized with poor effector functions and the expression of multiple inhibitory receptors. Objective: To inve...

Defective immunoregulatory T-cell function in chronic lymphocytic leukemia.

Chronic lymphocytic leukemia (CIL) of B-cell origin results in the malignant proliferation of small immunoglobulinbearing lymphocytes. There is currently a controversy in the literature regarding both the ability of this leukemic population to differentiate into mature plasma cells. as well as the ability of apparently normal T cells from these patients to regulate allogeneic B-cell differentia...

Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug.